Sort   by:  
 Page size 
GenomicsInferring expressed genes by whole-genome sequencing of plasma DNA
The analysis of cell-free DNA (cfDNA) in plasma represents a rapidly advancing field in medicine. cfDNA consists predominantly of nucleosome-protected DNA shed into the bloodstream by cells undergoing apoptosis. We performed whole-genome sequencing (WGS) of plasma DNA and identified two discrete reg...
EGAS00001001754 | EGA
GenomicsIdentification of mutations and structural rearrangements in plasma DNA form metastatic prostate cancer patients
In this study we analysed patients with metastatic prostate cancer to scan their tumor genomes noninvasively in plasma DNA. We enriched 1.3 Mbp of seven plasma DNAs (4 CRPC cases: CRPC1-3 and CRPC5; 3 CSPC cases: CSPC1-2 and CSPC4) including exonic sequences of 55 cancer genes and 38 introns of 18 g...
EGAS00001000453 | EGA
Genomicsena-DATASET-MUG-24-06-2016-10:36:41:861-335 - samples
Merged file of low-coverage WGS from 179 plasma DNA samples from non-cancer controls and cancer patients for assessment of size distribution of plasma nuclear DNA fragments.
EGAD00001002217 | EGA
Genomicsena-DATASET-MUG-10-03-2014-08:59:23:443-190 - samples
We utilized exome sequencing for DNA obtained from saliva (germline DNA) and the four spatially separated tumor foci and 3 corresponding lymph node metastases
EGAD00001000762 | EGA
Genomicsena-DATASET-MUG-26-02-2014-10:25:52:632-26 - samples
In this study we performed whole genome sequencing of plasma DNA (plasma-Seq) of 19 plasma-DNA samples from a total of 10 patients treated with anti-EGFR therapy. We demonstrated that development of resistance to anti-EGFR therapies is frequently associated with focal amplifications of KRAS, MET, an...
EGAD00001000748 | EGA
Genomicsena-DATASET-MUG-24-06-2016-09:45:40:262-333 - samples
Low coverage whole genome sequencing plasma DNA from 50 male, 54 female non-cancer donors. For the analysis of nucleosomal positioning all data from the non-cancer controls were merged. Furthermore, two patients with metastasized breast cancer were sequenced on a NextSeq with higher depth.
EGAD00001002215 | EGA
Genomicsena-DATASET-MUG-14-07-2016-11:57:14:452-1424 - samples
Single-end sequencing data (trimmed to 60bp) of 104 plasma samples from donors without tumors (male=50; female=54) were merged and used to establish coverage profiles around the TSS and to establish a gene expression prediction algorithm. Dataset includes merged alignements of low coverage whole gen...
EGAD00001002254 | EGA
Genomicsena-DATASET-MUG-29-10-2013-10:52:10:827-14 - samples
In this study we performed ultra deep sequencing of genes associated with anti-EGFR resistance, such as KRAS, BRAF, PIK3CA, and EGFR in 17 plasma-DNA samples from a total of 10 patients treated with anti-EGFR therapy.
EGAD00001000688 | EGA
GenomicsResistance to anti-EGFR therapy in colorectal cancer
Monoclonal antibodies targeting the Epidermal Growth Factor Receptor (EGFR), such as cetuximab and panitumumab, have evolved to important therapeutic options in metastatic colorectal cancer (CRC). However, almost all patients with clinical response to anti-EGFR therapies show disease progression wit...
EGAS00001000582 | EGA
Genomicsena-DATASET-MUG-19-03-2013-14:10:31:964-87 - samples
We performed low coverage whole genome sequencing of plasma DNA from prostate cancer patients to establish copy number profiles on both a genome-wide and a gene-specific level. The data include plasma samples from prostate cacner patients (n=13), non-malignant controls (males, n=10 and females, n=9)...
EGAD00001000364 | EGA
Sort   by:  
 Page size